Leflunomide
Arava, Leflunomide Zentiva (previously Leflunomide Winthrop) · ATC code L04AK01
Also known as: Leflunomid, Léflunomide, Leflunomida · Brand names: Arava, Leflunomide Zentiva, Leflon, Leflunomid Stada, Aramid, As-Lunex, Bageda, Lefumix, Lypathia, Ralef, Reumil
- Key facts
- Active substance
- Leflunomide
- Drug class
- Immunosuppressive drug
- ATC code
- L04AK01
- Authorisation
- centrally authorised across the EU (EMA)
- Dosage forms
- Arava 10 mg film-coated tablets · Arava 20 mg film-coated tablets · Arava 100 mg film-coated tablets · Leflunomide Zentiva 10 mg film-coated tablets · Leflunomide Zentiva 20 mg film-coated tablets · Leflunomide Zentiva 100 mg film-coated tablets
- Marketing authorisation holder
- Sanofi-aventis Deutschland GmbH, Zentiva k.s.
- Information as of
- 2026-10-27
Key facts
Leflunomide is an immunomodulating disease-modifying antirheumatic drug (DMARD). It is used in adults with active rheumatoid arthritis and active psoriatic arthritis.
What it is used for
- Active rheumatoid arthritis in adults (as a DMARD)
- Active psoriatic arthritis in adults
Dosing
- Rheumatoid arthritis: usually a loading dose of 100 mg once daily for 3 days, then 10 mg to 20 mg once daily depending on disease activity; omitting the loading dose may lower the risk of adverse events
- Psoriatic arthritis: 100 mg once daily for 3 days, then 20 mg once daily
- Effect usually starts after 4 to 6 weeks and may improve up to 4 to 6 months
- ALT and full blood count before starting, every two weeks for the first six months, then every 8 weeks
- No adjustment in mild renal insufficiency or above 65 years; not recommended below 18 years
Contraindications
- Hypersensitivity (especially previous Stevens-Johnson syndrome, TEN, erythema multiforme), including to teriflunomide
- Impaired liver function; moderate to severe renal insufficiency
- Severe immunodeficiency, significantly impaired bone marrow function, serious infections
- Severe hypoproteinaemia; pregnancy
Important warnings
- Rare severe liver injury, including fatal cases, mostly in the first 6 months; adhere strictly to monitoring
- Active metabolite has a long half-life (usually 1 to 4 weeks); use the washout procedure (colestyramine or activated charcoal) if toxicity occurs
- Concomitant hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) are not advisable
- Switching to another DMARD without washout may increase the risk of serious adverse reactions
Side effects
- Most frequent include mild increase in blood pressure, leucopenia, paraesthesia, headache, dizziness
- Diarrhoea, nausea, vomiting, oral mucosal disorders, abdominal pain
- Increased hair loss, eczema, rash, pruritus, dry skin
- Elevated liver parameters (especially ALT), weight loss, asthenia
Interactions
- Hepatotoxic or haematotoxic medicines: more side effects; monitor liver enzymes and blood counts closely after switching
- Methotrexate: liver enzyme elevations in a small study
- Colestyramine and activated charcoal rapidly lower levels of the active metabolite
Pregnancy and breastfeeding
- Contraindicated in pregnancy (suspected to cause serious birth defects)
- Effective contraception during and up to 2 years after treatment, or up to 11 days after a washout procedure
Summary of the official product information, written with AI on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.
Common questions – ask Medelix
For patients
Package leaflet, verbatim
Authorisation and brand names by country
Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.
EU – centrally authorised (all member states)
- AravaSanofi-aventis Deutschland GmbH · EMEA/H/C/000235
- Leflunomide medac · genericmedac Gesellschaft für klinische Spezialpräparate mbH · EMEA/H/C/001227
- Leflunomide ratiopharm · genericRatiopharm GmbH · EMEA/H/C/002035
- Leflunomide Zentiva (previously Leflunomide Winthrop)Zentiva k.s. · EMEA/H/C/001129
Source: European Medicines Agency (EMA), product information
Germany
- LeflonHeumann Pharma Gmbh & Co. Generica Kg · 2 register entries
- Leflunomid1 A Pharma Gmbh, Bluefish Pharmaceuticals Ab, Tillomed Pharma Gmbh, Heumann Pharma Gmbh & Co. Generica Kg, Aristo Pharma Gmbh (Art 57), Hexal Ag, Puren Pharma Gmbh & Co. Kg, Stadapharm Gmbh, Aliud Pharma Gmbh · 9 register entries
Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-28
Austria
- Leflunomid StadaStada Arzneimittel Gmbh · 1 register entry
Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-28
Turkey
- AramidKOÇAK FARMA İLAÇ VE KİMYA SAN. A.Ş. · 3 register entries
- AravaSANOFİ SAĞLIK ÜRÜNLERİ LTD. ŞTİ. · 3 register entries
- As-LunexAPOTEX İLAÇ SAN VE TİC. LTD. ŞTİ. · 2 register entries
- BagedaWORLD MEDICINE İLAÇ SAN. VE TİC. A.Ş. · 2 register entries
- LefumixNEUTEC İLAÇ SAN. TİC. A.Ş · 3 register entries
- LypathiaARDİ FARMA İLAÇ PAZARLAMA TİC. LTD. ŞTİ. · 2 register entries
- RalefGENVEON İLAÇ SAN. VE TİC. A.Ş. · 3 register entries
- ReumilABDİ İBRAHİM İLAÇ SAN. VE TİC. A.Ş. · 2 register entries
Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16
Brand names in 24 more European countries
- Belgium
- Leflunomid Sandoz, Leflunomide Ab
- Bulgaria
- Багеда
- Cyprus
- Arotan
- Czechia
- Leflon, Leflugen, Leflunomid Sandoz, Leflunopharm
- Denmark
- Leflunomid
- Estonia
- Leflunomide Elvim
- Finland
- Leflunomide Orion, Leflunomide Stada
- France
- Leflunomide Arrow, Leflunomide Biogaran, Leflunomide Eg, Leflunomide Viatris
- Greece
- Lefid, Lefluonia
- Hungary
- Leflunomid Sandoz
- Iceland
- Arava, Leflunomide Medac, Leflunomide Ratiopharm, Leflunomide Zentiva
- Ireland
- Leflunomide Aspire Pharma (Malta)
- Italy
- Leflunomide Aurobindo, Leflunomide Mylan, Leflunomide Sandoz
- Latvia
- Leflunomide Elvim, Leflunomide Sandoz
- Liechtenstein
- Arava, Leflunomide Medac, Leflunomide Ratiopharm, Leflunomide Zentiva
- Lithuania
- Leflunomide Elvim, Leflunomide Sandoz
- Malta
- Leflunomide Normon
- Netherlands
- Leflunomide Aurobindo, Leflunomide Cf, Leflunomide Sandoz, Leflunomide Tillomed, Leflunomide Viatris
- Norway
- Arava, Leflunomide Medac, Leflunomide Ratiopharm, Leflunomide Zentiva
- Poland
- Leflunomid Bluefish, Leflunomid Egis, Leflunomide Aurovitas, Leflunomide Orion, Leflunomide Sandoz
- Portugal
- Leflunomida Farmoz, Leflunomida Generis, Leflunomida Pentafarma
- Romania
- Leflon, Leflunomidă Arena, Leflunomidă Sandoz
- Spain
- Lefluartil, Leflunomida Aurovitas, Leflunomida Cinfa, Leflunomida Normon, Leflunomida Pharmathen, Leflunomida Stada, Leflunomida Tillomed, Leflunomida Viatris
- Sweden
- Leflunomid Bluefish
EMA – Article 57 product data (EU/EEA), 2026-10-28
Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.
Other substances in the same group
Another question about this substance?
Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.
Sources
- European Medicines Agency. Arava – EPAR, Product Information. 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/arava-epar-product-information_en.pdf
- European Medicines Agency. Leflunomide Zentiva (previously Leflunomide Winthrop) – EPAR, Product Information. 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/leflunomide-zentiva-epar-product-information_en.pdf
- EMA – Article 57 product data (EU/EEA), 2026-10-28. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
- EMA – Article 57 product data (EU/EEA), 2026-10-28. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
- TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
- Wikidata (CC0): ATC L04AK.
Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error
Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.